Journey Medical Corporation (DERM:NASDAQ) closed at $4.33 on November 13, 2026, down 1.37% on the day. The stock trades 54.7% below its 52-week high of $9.56 and 8.3% above its 52-week low of $4.00. Over the past year, it lost 45.1%. Journey Medical Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, DERM closed higher on 125 days (50%). Its best day was May 14, 2026 (+22.35%) and its worst was March 26, 2026 (-30.01%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 2 times.
Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Find more stocks like DERM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.